The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind.

In November, the U.S. FDA approved Ixchiq as the world’s first chikungunya vaccine. The company reported 28-day and six-month data from the VLA1553-321 trial in 2023 and 2024, respectively.

In November 2023, the FDA approved Ixchiq for the prevention of disease caused by the chikungunya virus in patients age 18 years and older. On Friday, health officials said the FDA will conduct an ...

Ixchiq was approved in 2023 and has been distributed globally with 80,000 doses administered so far. Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 Days - Get The Details Now ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026.

Valneva (NASDAQ:VALN) ADRs fell on Wednesday after the French biotech said that the EU drug regulator, the European Medicines Agency (EMA), has suspended the use of its chikungunya vaccine, Ixchiq ...

The FDA approved the vaccine for the prevention of chikungunya virus in adults aged 18 years or older who are at increased risk for exposure, and the vaccine contains a live, though weakened ...

As of May 7, 17 serious events, including two deaths, have been reported in people ages 62 to 89 who received the Ixchiq vaccine. Six of the reports have been in the U.S.

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 and older, including death.

Immune response was evaluated in 362 participants (266 treated with Ixchiq and 96 with placebo). At 28 days after vaccination, 98.9% of individuals who received the vaccine had antibody titers ...

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ amid a safety review. Read more here.